Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07285707

Acupuncture and Chinese Herbal Medicine for Long COVID

List of the Hypothesis:

Primary hypothesis: A flexible acupuncture and Chinese herbal medicine protocol will be feasible, acceptable, and useful for the treatment of long COVID.

Secondary hypothesis: Long COVID patients receiving acupuncture treatment or acupuncture treatment and Chinese herbal supplements over an 8-week period will see improvements in their symptoms, function, and quality of life measurements.

Specific Aims of This Research (Purpose of the study):

To study the feasibility, acceptability and utility of an acupuncture and Chinese herbal supplement treatment protocol for patients with long COVID and preliminarily assess the effects of treatment.

Currently Available Research on This Subject:

Studies indicate that acupuncture can effectively treat symptoms that are similar to those often seen in long COVID patients. Additionally, recent studies and clinical evidence suggest that there is substantial potential for acupuncture in the treatment of long COVID. Acupuncture may be beneficial because it can address many symptoms simultaneously with a single intervention, whereas symptom clusters can be difficult to manage with pharmaceuticals due to the need for multiple pharmaceutical agents.

Summary of the research protocol/methodology:

Five patients will receive acupuncture treatment, and five patients will receive acupuncture and Chinese herbal medicine. Each participant will receive 16 acupuncture treatments over the course of eight weeks (i.e., twice per week). Each treatment session will last for 30 minutes. Follow-up will occur at 12 weeks (i.e., four weeks after the final treatment session).

Significance of this research to the health and welfare of general public:

There is currently not a single, specific treatment for long COVID. If acupuncture treatment alone and/or acupuncture and Chinese herbal medicine combined are feasible, acceptable, and efficacious in the improvement of long COVID symptoms, it will offer patients additional treatment options, which may help some patients to avoid pharmaceutical treatment side effects or polypharmacy challenges.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Long COVID COVID-19 Chronic Disease Coronaviridae Infections Coronavirus Infections Disease Attributes Infections Lung Diseases Nidovirales Infections Pathologic Processes Pathological Conditions, Signs and Symptoms Pneumonia Pneumonia, Viral Post-Acute COVID-19 Syndrome Post-Infectious Disorders RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

SCUHS

Whittier, California, 90604, United States

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years of age or older
  • We will include adults of any age in our study. Adults of all ages can experience long COVID symptoms, although it is more common in older adults
  • Confirmed and documented COVID-19 illness (confirmed by healthcare provider or test; acceptable documentation includes but is not limited to a doctor's note or a photo of test result)
  • COVID-19 illness is a necessary precursor to the development of long COVID
  • Experiencing at least one of the following common long COVID symptoms for at least 4 weeks after confirmed COVID-19 illness:
  • Fatigue or post-exertional malaise,
  • Dyspnea, cough,
  • Brain fog, sleep disturbance, depression, anxiety,
  • Arthralgia, myalgia, or
  • Constipation, diarrhea, stomach pain
  • Over 200 different long COVID symptoms have been identified. The proposed study is a small pragmatic pilot study which only plans to enroll 10 participants. It is necessary to limit inclusion to some of the most common symptoms to ensure that the findings are broadly relevant across the long COVID patient population.
  • The symptoms were not present prior to the confirmed COVID-19 illness

o If the symptoms were present prior to the confirmed COVID-19 illness, then they are most likely attributable to a cause other than long COVID

  • Willingness to comply with the treatment schedule

o It is important that all those who qualify for the study are willing to comply with the protocol that is being adopted. If the patient is not willing to attend acupuncture treatment sessions or comply with the supplement schedule, then they may not be enrolled in the study.

  • Ability to read and understand English o Informed consent will be in the English language. Inability to read and understand English will interfere with provision of informed consent. Moreover, compliance is a potential issue with herbal supplementation. Recruiting patients who are able to read and understand English instructions for supplement intake will help to improve compliance with the protocol.
  • Ability to provide informed consent o It is important that participants are aware that they are required to provide written informed consent before they are allowed to participate. Some individuals who are eligible might be unwilling to sign the informed consent form.

Exclusion criteria

  • • Under 18 years of age
  • Pulmonary fibrosis or on continuous oxygen treatment
  • Certain preexisting conditions:
  • Diagnosed with Alzheimer's or demonstrating onset of dementia
  • Uncontrolled hypertension, diabetes, or autoimmune conditions
  • Other comorbid conditions that might imitate long COVID symptoms
  • Undergoing cancer treatments
  • Use of acupuncture or Chinese medicine in the past three months
  • Involved in health-related litigation or legal claims
  • Missing either baseline visit and deemed unlikely to comply with the study protocol
  • Pregnant or breastfeeding or trying to get pregnant

Treatment and study plan

Acupuncture

Procedure

The investigators have developed a list of core acupoints, which will be used by all clinicians for each specific TCM diagnosis pattern identified in each patient. Similarly, a list of common herbal formulas, that we will keep in stock based on the specific diagnosis patterns, has been developed. Clinicians will have the option of using additional acupoints as necessary and will be asked to record and explain any variations from the core protocol.

  • Residual Heat: LI-11, KI-6;Bai He Gu Jin Tang
  • Residual Phlegm: ST-40, Sp-9;Ban Xia Bai Zhu Tian Ma Tang,Er Chen Tang
  • Deficiency of Spleen: SP-3, ST-36;Gui Pi Tang,Xiang Sha Liu Jun Zi Tang
  • Lung Qi Deficiency with Dampness: LU-9, LU-7;Zhi Sou San,Er Chen Tang
  • Blood Stagnation: SP-10, SP-6;Xue Fu Zhu Yu Tang,Tao Hong Si Wu Tang
  • Deficiency of Lung: LU-9, LU-7; Bu Fei Tang
  • Liver Qi Stagnation: LV-3, PC-6;Xiao Yao San, Chai Hu Shu Gan Tang
  • Yin Deficiency: KI-6, SP-6;Liu Wei Di Huang Wan
  • Deficiency of Kidney: KI-3, KI-6;

Primary outcomes

  1. Feasibility of Implementing a Combined Acupuncture and Chinese Herbal Medicine Intervention for long COVID

    Time frame: From enrollment to the final follow-up at 12 weeks

    Feasibility will be measured through a feasibility assessment questionnaire which will evaluate recruitment, retention, and adherence metrics across the 12-week intervention and the final follow-up. Feasibility indicators will be summarized as proportions and descriptive statistics to evaluate the practicality of the study procedures and protocol implementation.

Secondary outcomes

  1. Patient-Reported Acceptability of the Study Procedures and Treatments

    Time frame: Week 12 (final follow-up).

    Acceptability will be evaluated using a participant satisfaction questionnaire administered at the end of the 12-week intervention. The survey includes Likert-scale items (1 = very dissatisfied to 5 = very satisfied) assessing participants' comfort with study procedures, satisfaction with the acupuncture and herbal treatment, and willingness to recommend participation to others. Mean scores will be calculated; higher scores indicate greater acceptability and satisfaction with the study protocol and treatment experience

  2. Clinician-Reported Acceptability of the Study Protocol

    Time frame: Week 12 (final follow-up).

    Clinician acceptability will be measured through a self-administered survey at the end of the 12-week intervention. The survey uses a 5-point Likert scale (1 = very dissatisfied to 5 = very satisfied) to assess satisfaction with the clinical feasibility, workflow, and perceived patient benefit of the combined acupuncture and herbal medicine protocol. Scores will be averaged, and higher scores indicate greater clinician-reported acceptability.

  3. Change in Health-Related Quality of Life Measured by PROMIS-29 v2.1

    Time frame: Baseline, Week 4, Week 8, and Week 12.

    Quality of life will be assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS-29 v2.1) at baseline, mid-intervention, and post-intervention. The PROMIS-29 measures physical function, anxiety, depression, fatigue, sleep disturbance, pain interference, and social participation. Each domain produces a standardized T-score (mean = 50, SD = 10). Higher scores represent better functioning for positive domains and greater symptom burden for negative domains. Changes from baseline to Week 12 will reflect improvements or declines in overall quality of life.

  4. Change in Symptom Burden Measured by the Symptom Burden Questionnaire for Long COVID (SBQ™-LC)

    Time frame: Baseline, Week 8, and Week 12.

    Symptom burden will be assessed using the Symptom Burden Questionnaire for Long COVID (SBQ™-LC). At baseline, participants complete all domains; at Weeks 8 and 12, they complete up to four domains corresponding to their most bothersome baseline symptoms, as well as the mandatory Mental Health and Well-Being domain. Each item is rated from 0 (no symptom) to 10 (worst possible symptom). Higher scores indicate greater symptom severity. Domain and total scores will be compared across time points to evaluate changes in symptom burden.

  5. Change in Whole Health Person Index (WHPI)

    Time frame: Baseline, Week 8, and Week 12.

    Overall well-being will be measured using the Whole Health Person Index (WHPI), a 0-100 scale that assesses physical, emotional, and social wellness. Higher scores indicate better overall health and life balance. The change in WHPI from baseline to Week 12 will be used to evaluate perceived improvements in general well-being associated with the intervention.

  6. Change in Laboratory Biomarkers - Complete blood count

    Time frame: Baseline and Week 8.

    Laboratory values will be compared from baseline to Week 8 to assess physiological effects of the intervention. Test includes complete blood count (CBC) with differential. Changes in this marker will indicate biological trends in inflammation.

  7. Incidence and Severity of Adverse Events Associated with Acupuncture and Herbal Medicine

    Time frame: Throughout the 12-week study period

    Safety will be monitored throughout the 12-week study by documenting adverse events (AEs) and serious adverse events (SAEs) related to acupuncture or herbal supplementation. Each event will be recorded in Qualtrics using the Adverse Event Form and graded as mild, moderate, or severe per Institutional Review Board (IRB) and Common Terminology Criteria for Adverse Events (CTCAE v5.0) guidelines. Frequency and type of AEs will be summarized descriptively as counts and percentages.

  8. Change in Laboratory Biomarkers - Comprehensive metabolic panel

    Time frame: Baseline and Week 8.

    Laboratory values will be compared from baseline to Week 8 to assess physiological effects of the intervention. Test includes complete comprehensive metabolic panel (CMP). Changes in this marker will indicate biological trends in inflammation and metabolic function.

  9. Change in Laboratory Biomarkers - C-reactive protein

    Time frame: Baseline and Week 8.

    Laboratory values will be compared from baseline to Week 8 to assess physiological effects of the intervention. Test includes C-reactive protein (CRP). Changes in this marker will indicate biological trends in inflammation.

  10. Change in Laboratory Biomarkers - Erythrocyte sedimentation rate

    Time frame: Baseline and Week 8.

    Laboratory values will be compared from baseline to Week 8 to assess physiological effects of the intervention. Test includes erythrocyte sedimentation rate (ESR). Changes in this marker will indicate biological trends in inflammation.

  11. Change in Laboratory Biomarkers - Tumor necrosis factor-alpha

    Time frame: Baseline and Week 8.

    Laboratory values will be compared from baseline to Week 8 to assess physiological effects of the intervention. Test includes tumor necrosis factor-alpha. Changes in this marker will indicate biological trends in inflammation and metabolic function.

  12. Change in Laboratory Biomarkers - thyroid panel

    Time frame: Baseline and Week 8.

    Laboratory values will be compared from baseline to Week 8 to assess physiological effects of the intervention. Test includes thyroid panel. Changes in this marker will indicate biological trends in metabolic function.

  13. Change in Laboratory Biomarkers - Vitamin D levels.

    Time frame: Baseline and Week 8.

    Laboratory values will be compared from baseline to Week 8 to assess physiological effects of the intervention. Tests include vitamin D levels. Changes in these markers will indicate biological trends in inflammation and metabolic function.

Study contacts

Contact information is provided by the study sponsor or research team.

Leah Grout, PhD, MPH

CONTACT

[email protected]

562-902-3365

S. Prasad Vinjamury, MD (Ayurveda) DACM, MPH

CONTACT

[email protected]

562-947-8755 ext. ext:736

Sponsors and collaborators

Lead sponsor

Southern California University of Health Sciences

Other

Registry information

Official study title

Acupuncture for Long COVID - A Pragmatic Pilot Study

Acronym: ACUCM-LC

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Dec 16, 2025
Registry last updated
Dec 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.